Inhibikase Therapeutics, Inc. Balance Sheet

Balance Sheet Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Assets
Current Assets
Cash & Equivalents 13.95M40.75M7.19M9.17M56.49M
Short-term Investments 15.86M4.09M41.05M
Cash & Current Investments 13.95M40.75M23.05M13.25M97.54M
Receivables - Net 0.11M0.04M
Receivables 0.11M0.04M
Prepaid Assets 0.77M1.50M1.12M0.74M0.83M
Current Assets 14.78M42.47M24.37M14.21M98.45M
Non-Current Assets
Property, Plant & Equipment (Net) 0.24M0.07M0.05M
Non-Current Assets 0.57M0.30M0.15M
Assets 14.78M42.47M24.94M14.51M98.60M
Liabilities
Current Liabilities
Accounts Payables 1.72M1.09M1.15M0.65M0.94M
Notes Payables 0.32M0.25M
Payables 2.04M1.34M1.15M0.65M0.94M
Accumulated Expenses 0.63M2.72M2.40M2.26M2.68M
Other Accumulated Expenses 0.05M0.01M0.01M0.10M0.08M
Short term Debt 0.15M0.15M0.11M
Current Deferred Revenue 2.33M
Total Current Liabilities 4.72M4.05M3.70M3.44M3.73M
Non-Current Liabilities
Capital Leases 0.21M0.09M
Non-Current Debt 0.28M
Total Liabilities 5.00M4.05M3.90M3.53M3.73M
Shareholder's Equity
Total Debt 0.28M0.15M0.15M0.11M
Common Equity 9.78M38.42M21.04M10.98M94.87M
Shareholder's Equity 9.78M38.42M21.04M10.98M94.87M
Liabilities and Shareholders Equity 14.78M42.47M24.94M14.51M98.60M
Retained Earnings 15.03M-29.82M-47.87M-66.90M-94.42M